Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 3
Abstract
In the session on “Pharmacodynamic studies to demonstrate efficacy and safety”, presentations were made on methods of evaluating airway deposition of inhaled corticosteroids and bronchodilators, and systemic exposure indirectly using pharmacodynamic study designs. For inhaled corticosteroids, limitations of measuring exhaled nitric oxide and airway responsiveness to adenosine for anti-inflammatory effects were identified, whilst measurement of 18-h area under the cortisol concentration–time curve was recommended for determining equivalent systemic exposure. For bronchodilators, methacholine challenge was recommended as the most sensitive method of determining the relative amount of β-agonist or anti-muscarinic agent delivered to the airways. Whilst some agencies, such as the Food and Drug Administration (FDA), do not require measuring systemic effects when pharmacokinetic measurements are feasible, the European Medicines Agency requires measurement of heart rate and serum potassium, and some require serial electrocardiograms when bioequivalence is not established by pharmacokinetic (PK) studies. The Panel Discussion focused on whether PK would be the most sensitive marker of bioequivalence. Furthermore, there was much discussion about the FDA draft guidance for generic fluticasone propionate/salmeterol. The opinion was expressed that the study design is not capable of detecting a non-equivalent product and would require an unfeasibly large sample size.
Authors and Affiliations
Leslie Hendeles, Peter T. Daley-Yates, Robert Hermann, Jan De Backer, Sanjeeva Dissanayake, Stephen T. Horhota
Keywords
Related Articles
- EP ID EP680961
- DOI 10.1208/s12248-015-9735-7
- Views 45
- Downloads 0
A photo-crosslinked poly(vinyl alcohol) hydrogel growth factor release vehicle for wound healing applications
The objective of this study was to develop and evaluate a hydrogel vehicle for sustained release of growth factors for wound healing applications. Hydrogels were fabricated using ultraviolet photo-crosslinking of acrylam...
A Qualitative and Quantitative Proteomic Study of Human Microdialysate and the Cutaneous Response to Injury
The online version of this article (doi:10.1208/s12248-011-9269-6) contains supplementary material, which is available to authorized users.
“Fit-for-Purpose” Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies
Biomarkers are used to study drug effects, exposure–response relationships, and facilitate early decision making during development. Denosumab, a fully human monoclonal antibody against receptor activator of nucl...
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was teste...
O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII
Factor VIII (FVIII) is an important cofactor in the blood coagulation cascade. A deficiency or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding disorder. FVIII circulates in plasma as a heterodimer c...